These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 7398758

  • 1. Selective storage in vivo of 5,6-ADTN in dopamine-rich areas of the rat brain.
    Westerink BH, Dijkstra D, Feenstra MG, Horn AS, Rollema H.
    Eur J Pharmacol; 1980 Jun 13; 64(2-3):115-21. PubMed ID: 7398758
    [Abstract] [Full Text] [Related]

  • 2. The significance of COMT activity in controlling dopamine agonist levels in brain and serum: studies with a prodrug and a metabolite of 6,7-ADTN.
    Rollema H, Westerink BH, Mulder TB, Dijkstra D, Feenstra MG, Horn AS.
    Eur J Pharmacol; 1980 Jun 27; 64(4):313-23. PubMed ID: 7389825
    [Abstract] [Full Text] [Related]

  • 3. A prodrug of ADTN: selectivity of dopaminergic action and brain levels of ADTN.
    Horn AS, Kelly P, Westerink BH, Dijkstra D.
    Eur J Pharmacol; 1979 Nov 23; 60(1):95-9. PubMed ID: 574829
    [Abstract] [Full Text] [Related]

  • 4. Similar binding of 3H-ADTN and 3H-apomorphine to calf brain dopamine receptors.
    Seeman P, Woodruff GN, Poat JA.
    Eur J Pharmacol; 1979 Apr 15; 55(2):137-42. PubMed ID: 456412
    [Abstract] [Full Text] [Related]

  • 5. Effects of ADTN and various other 2-aminotetralin derivatives on the efflux of 3H-dopamine from rat striatal slices.
    Mulder AH, Braakhuis B, De Regt V, Dijkstra D, Horn AS.
    Eur J Pharmacol; 1980 Jun 27; 64(4):349-55. PubMed ID: 7389827
    [Abstract] [Full Text] [Related]

  • 6. Properties of dopamine agonist and antagonist binding sites in mammalian retina.
    Makman MH, Dvorkin B, Horowitz SG, Thal LJ.
    Brain Res; 1980 Aug 04; 194(2):403-18. PubMed ID: 6770965
    [Abstract] [Full Text] [Related]

  • 7. S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects.
    Rollema H, Feenstra MG, Grol CJ, Lewis MH, Staples L, Mailman RB.
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Apr 04; 332(4):338-45. PubMed ID: 3736679
    [Abstract] [Full Text] [Related]

  • 8. Altered characteristics of striatal [3H]ADTN binding following substantia nigra lesions.
    Hirschhorn ID, Makman MH.
    Eur J Pharmacol; 1982 Sep 10; 83(1-2):61-7. PubMed ID: 7128701
    [Abstract] [Full Text] [Related]

  • 9. Striatal binding of 2-amino-6,7-[3H]dihydroxy-1,2,3,4-tetrahydronaphthalene to two dopaminergic sites distinguished by their low and high affinity for neuroleptics.
    List SJ, Wreggett KA, Seeman P.
    J Neurosci; 1982 Jul 10; 2(7):895-906. PubMed ID: 6124583
    [Abstract] [Full Text] [Related]

  • 10. [3H] 2-Amino-6,7-dihydroxy 1,2,3,4-tetrahydronapthalene (ADTN): a potential specific dopamine receptor ligand.
    Clement-Cormier Y, Abel M.
    Res Commun Chem Pathol Pharmacol; 1978 Oct 10; 22(1):15-25. PubMed ID: 725314
    [Abstract] [Full Text] [Related]

  • 11. [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalen (ADTN). Regional distribution and in vivo binding after acute and chronic drug treatment.
    Clement-Cormier Y, Smith CE.
    Neurochem Res; 1980 Jun 10; 5(6):641-51. PubMed ID: 7402434
    [Abstract] [Full Text] [Related]

  • 12. Changes in guanine nucleotide sensitive and insensitive 3H-ADTN binding in striatum following substantia nigra lesions.
    Hirschhorn ID, Makman MH, Gardner EL.
    Eur J Pharmacol; 1980 Mar 07; 62(1):123-4. PubMed ID: 6154585
    [No Abstract] [Full Text] [Related]

  • 13. The uptake and release of [3-H]-2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthlane (ADTN) by striatal nerve terminals.
    Davis A, Roberts PJ, Woodruff GN.
    Br J Pharmacol; 1978 May 07; 63(1):183-90. PubMed ID: 647158
    [Abstract] [Full Text] [Related]

  • 14. In vivo dopamine receptor binding studies with a non-radioactively labeled agonist, dipropyl-5,6-ADTN.
    Feenstra MG, Rollema H, Mulder TB, Westerink BH, Horn AS.
    Life Sci; 1983 Mar 21; 32(12):1313-23. PubMed ID: 6403788
    [Abstract] [Full Text] [Related]

  • 15. The use of ADTN (2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene) as a ligand for brain dopamine receptors [proceedings].
    Cross AJ, Crow TJ, Owen F.
    Br J Pharmacol; 1979 May 21; 66(1):87P. PubMed ID: 454971
    [No Abstract] [Full Text] [Related]

  • 16. Brain levels and metabolism of the dopaminergic agonist 2-amino-6,7-dihydroxytetrahydronaphthalene after administration of various prodrugs.
    Horn AS, Griever-Kazemier H, Dijkstra D.
    J Med Chem; 1982 Aug 21; 25(8):993-6. PubMed ID: 7120289
    [Abstract] [Full Text] [Related]

  • 17. Involvement of both dopaminergic and alpha-adrenergic receptors in the hypomotility induced by dibenzoyl-6,7-ADTN.
    Sumners C, De Vries JB, Dijkstra D, Horn AS.
    Eur J Pharmacol; 1981 Apr 09; 70(4):541-50. PubMed ID: 6113149
    [Abstract] [Full Text] [Related]

  • 18. Binding of [3H]ADTN to rat striatal membranes.
    Templeton WW, Woodruff GN.
    Biochem Pharmacol; 1982 Apr 15; 31(8):1629-32. PubMed ID: 6124259
    [Abstract] [Full Text] [Related]

  • 19. Use of ADTN to define specific 3H-spirerone binding to receptors in brain.
    Quik M, Iversen LL, Larder A, Mackay AV.
    Nature; 1978 Aug 03; 274(5670):513-4. PubMed ID: 672981
    [No Abstract] [Full Text] [Related]

  • 20. Uptake of (3H)-ADTN into dopaminergic neurons in the rabbit retina.
    Ehinger B.
    Acta Physiol Scand; 1981 Apr 03; 111(4):511-2. PubMed ID: 7304214
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.